Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Semler Scientific ( (SMLR) ) just unveiled an update.
Semler Scientific has reported a decline in the usage of its QuantaFlo device due to changes in Medicare Advantage and Part D rates, with a significant customer planning to reduce its usage from October 1, 2025. This is expected to result in a substantial drop in fourth-quarter revenues for 2025. Additionally, the company faces a lawsuit filed on August 29, 2025, by a stockholder alleging violations of securities laws, which Semler Scientific intends to contest.
The most recent analyst rating on (SMLR) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.
Spark’s Take on SMLR Stock
According to Spark, TipRanks’ AI Analyst, SMLR is a Neutral.
Semler Scientific’s overall stock score reflects a mix of strong strategic initiatives and financial challenges. The company’s robust Bitcoin strategy and stable balance sheet are positive factors, but declining revenues and bearish technical indicators weigh on the score. The valuation is reasonable, but the lack of a dividend yield is a drawback for some investors.
To see Spark’s full report on SMLR stock, click here.
More about Semler Scientific
Semler Scientific operates in the healthcare industry, focusing on cardiovascular testing products. Its primary product, QuantaFlo, aids in diagnosing cardiovascular diseases, and the company is actively seeking FDA clearance for expanded labeling.
Average Trading Volume: 760,682
Technical Sentiment Signal: Sell
Current Market Cap: $420.3M
Learn more about SMLR stock on TipRanks’ Stock Analysis page.